Pacer Advisors
SAGE

Pacer Advisors’s Sage Therapeutics SAGE Stock Holding History

Pacer Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-701
Closed -$7.61K – 2679
2024
Q2 		$7.61K Sell
701
-1,125
-62% -$14.4K ﹤0.01% 3588
2024
Q1 		$34.2K Buy
+1,826
New +$42.1K ﹤0.01% 3318
2021
Q2 		– Sell
-991
Closed -$74K – 1539
2021
Q1 		$74K Sell
991
-962
-49% -$78.9K ﹤0.01% 1352
2020
Q4 		$169K Sell
1,953
-950
-33% -$70K ﹤0.01% 1264
2020
Q3 		$177K Buy
+2,903
New +$147K ﹤0.01% 1199
2018
Q4 		– Sell
-1,653
Closed -$233K – 946
2018
Q3 		$233K Buy
+1,653
New +$255K 0.01% 999
2018
Q1 		– Sell
-825
Closed -$136K – 1116
2017
Q4 		$136K Buy
+825
New +$80K 0.01% 935

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Pacer Advisors's SAGE Position: Q3 2024 in Review

Pacer Advisors sold out of Sage Therapeutics (SAGE) in Q3 2024, closing a stake of 701 shares — an estimated $7.61K sold.

Pacer Advisors first reported a position in SAGE in Q4 2017 and held it in 7 quarters. The position peaked at $233K in Q3 2018. 176 funds tracked by Wall St. Rank hold SAGE as of Q3 2024.

  • Pacer Advisors reported no remaining Sage Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 701 Sage Therapeutics shares in Q3 2024, an estimated $7.61K.
  • Pacer Advisors first reported a position in Sage Therapeutics in Q4 2017 and held it in 7 quarters.
  • Pacer Advisors's Sage Therapeutics position peaked at $233K in Q3 2018.
  • 176 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.